The changing concept of the metabolic syndrome in the past two decades;A metabolikus szindróma koncepciójának változása az elmúlt két évtizedben

Lege Artis Medicinae

Volumn 20, Issue 1, 2010, Pages 21-30

  Halmos, Tamás ^a,b   Suba, Ilona ^a  

^a Metabolikus Ambulancia ^*  (Hungary)

^b Jewish Charity Hospital   (Hungary)

Author keywords

Alzheimer disease; Depression; Malignant diseases; Metabolic syndrome; Nonalcoholic fatty liver; Pathomechanisms; Slee apnoe

Indexed keywords

EID: 76849094822     PISSN: 08664811     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Halmos T. A metabolikus szindróma legújabb vonatkozásai. LAM 1998;8(2):84-95.
2. 2. DeFronzo RA, Ferrannini, E. Insulin Resistance a multifaceted Syndrome, responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:174-84.
3. Stern MP. Diabetes and cardiovascular disease - the "common soil hypothesis". Diabetes 1995;44:369-74.
4. Davidson MB. Metabolic Syndrome/Insulin Resistance Syndrome/Prediabetes. New section in Diabetes Care 2003;26:317.
5. Hales CN, Ozanne SE. Fetal and early postnatal growth restriction lead to diabetes, metabolic syndrome and renal failure. Diabetologia 2003;46:1013-9.
6. Nobili V Alisi A, Panera N, Agostoni C. Low birth weight and catch-up-growth associated with metabolic syndrome: a ten year systematic review. Pediatr Endocrinol Rev 2008;6(2):241-7.
7. 7. Reinehr T, Kleber M, Toschke AM. Small for gestational age status is associated with metabolic syndrome in overweight children. Eur J Endocrinol 2009;160(4):579-84.
8. Neel JV Diabetes mellitus. A thrifty genotype rendered detrimental by progress? Am J Hum Genet 1962;14:353-62.
9. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus; provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
10. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Croup for the study of insulin resistance (EGIR). Diabet Med 1999;16:442-3.
11. National Cholesterol Education Program (NCEP). Expert panel on Detection and Treatment of high Blood Cholesterol in Adults (2002). Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation and Treatment of high Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
12. Waterhouse DF, McLaughlin AM, Sheehan F O'Shea D. An examination of the prevalence of IDF and ATPIII-defined metabolic syndrome in an Irish screening population. Ir J Med Sci 2009; 178(2):161-6.
13. Eriksson J, Taimela S, Koivisto VA. Exercise and the metabolic syndrome. Diabetes 1997;40:125-35.
14. Epidemiology Diabetes Voice 2006;51:5-7 (Editorial).
15. Keane J, Meier JL, Noth RH, et al. Computer-Based Screening of Veterans for Metabolic Syndrome. Metab Syndr Relat Disord. 2009 Jun 26. [Epub ahead of print]
16. Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. NEJM 2004;350:2362-74.
17. 7. Shao J, Yamashita H, Qiao L, Friedman JE. Decreased Akt kinase activity and insulin resistance in C57BL/KsJ-Leprdb/db mice. Journal of Endocrinology 2000;167:107-115.
18. Stout RW. Insulin and atheroma 20 year perspective. Diab Care 1990;13:631-54.
19. Himsworth HP, Kerr RB. Insulin-sensitive and insulin-insensitive types of diabetes mellitus. Clin Sci 1939;4:119-52.
20. Duckworth WC. Hyperglycemia and cardiovascular disease. Current Atherosclerosis Reports 2001;3:383-91.
21. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-56.
22. Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech 2009;2(5-6):231-7.
23. Lee JS, Kim SH, Jun DW, et al. Clinical implications of fatty pancreas: correlations between fatty pancreas and metabolic syndrome. World J Gastroenterol 2009;15(15):1869-75.
24. Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest 2006;116:1813-22.
25. Reaven GM. The metabolic syndrome: is this diagnosis necessary? American Journal of Clinical Nutrition 2006;83:1237-47.
26. Cubbon RM, Kahn MB, Wheatcroft SB. Effects of insulin resistance on endothelial progenitor cells and vascular repair. Clin Sci (London) 2009;117(5) :173-90.
27. Egan BM. Inzulin rezisztencia és a szimpathikus idegrendszer. Current Hypertension Reports Magyarnyelvu kiadás 2003;3:644-52.
28. Jeppesen J, Hein HO, Suadicani P, Gynterberg F. Low triglycerideshigh high-density lipoprotein cholesterol and risk of ischemic heart disease. Arch Intern Med 2001;16:361-6.
29. Ahima RS, Frier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000;11:327-32.
30. Jakab L. Az atherosclerosis patogenezise. Orv Hetil 2003;144: 1121-8.
31. Lastra-Lastra G, Sowers JR, Restrepo-Erazo K, Manrique-Acevedo C, Lastra-González G. Role of aldosterone and angiotensin II in insulin resistance: an update. Clin Endocrinol (Oxf) 2009;71(1): 1-6.
32. Björntorp P, Rosmond R. The metabolic syndrome - a neuroendocrine disorder? 1: Br J Nutr 2000;83(Suppl1):S 49-57.
33. Wilson TM, Brown PJ, Sternbach DD, et al. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000;43:527-50.
34. Sewter C, Vidal-Puik A. PPAR(gamma) and thiazolidine-diones: molecular basis for a treatment of "Syndome X"? Diabetes Obes Metab 2002;4:239-48.
35. Bajnok L, Paragh Gy. Lipid modulált transzkriptios faktorok szerepe az energiaháztartás szabályozásában. Metabolizmus 2003;1/4: 192-8.
36. Oliver WR. Jr, Shenk JL, Snaith MR, et al. Selective peroxisome proliferator-activated receptor delta agonists promotes reverse cholesterol transport. Proc Natl Acad Sci USA 2001;98:5306-11.
37. Duan SZ, Usher MG, Mortensen RM. PPARs: the vasculature, inflammation and hypertension. Curr Opin Nephrol Hypertens 2009;18(2):128-33.
38. Jung T, Catalgol B, Grune T. The proteasomal system. Mol Aspects Med 2009;30(4): 191-296.
39. Lee DH, Lee IK, Porta M, Steffes M, Jacobs DR Jr. Relationship between serum concentrations of persistent organic pollutants and the prevalence of metabolic syndrome among non-diabetic adults: results from the National Health and Nutrition Examination Survey 1999-2002. Diabetologia 2007;9:1841-51.
40. Kahn R, Buse J, Ferrannini E, Stern M. ADA statement the metabolic sdrome: Time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289-304.
41. Reaven GM. Counterpoint: just being alive is not good enough. Clin Chem 2005;51:1354-7.
42. Grundy SM. The Metabolic Syndrome: a multiple risk factor. J Clin Endocrinol Metab 2007;92:398-404.
43. Halmos T, Suba I. A metabolikus szindrómáról és a 2-es típusú diabetesrol kicsit más képpen. Orvostovábbképzo Szemle 2009; XVI(4):13-21.
44. Halmos T, Suba I. A metabolikus szindróma és a 2-es típusú diabetes mellitus mint rosszindulatú daganatra hajlamosító állapotok. Orv Hetil 2008;149:2403-12.
45. Stattin P, Björ O, Ferrari P, et al. Prospective study of hyperglycemia and cancer risk. Diab Care 2007;30(3):561-7.
46. Jee SH, Ohrr H, Suli JW, et al. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005;293(2):194-202.
47. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Owerweight, obesity and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625-38.
48. Suba Zs, Barabás J, Szabó Gy, et al. Increased prevalence of diabetes and obesity in patients with salivary gland tumors. Diabetes Care 2005;28:228-30.
49. Gillies RJ, Gatenby RA. Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer Metastasis Rev 2007;26: 311-7.
50. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005;202:654-62.
51. Jing MA, Giovanucci E, Pol lak M, et al. A prospective study of plasma C-peptide and colorectal cancer risk in men. Journal of the National Cancer Institute 2004;96(7):546-53.
52. Clodfelder-Miller BJ, Zmijewska AA, Johnson GV, Jope RS. Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency. Diabetes 2006;55(12): 3320-25.
53. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acata Psychiatr Scand 2009;119(1):4-14.
54. Giora Pillar, Naim Shehadeh. Abdominal Fat and Sleep Apnea. The chicken or the egg? Diab Care 2008;31 :S303-S309.
55. Ryan CM, Wilsin AM, Slavin J, et al. Association between liver histology and severity of the metabolic syndrome in subjects with non alcoholic fatty liver disease. Diab Care 2005;28:1222-4.
56. Roux F, D'Ambrosio C, Mohsenin D. Sleep related breathing disorder and cardiovascular disease. AM J Med 2000;108:396-401.
57. Watz H, Waschki B, Kirsten A, et al. The Metabolic Syndrome in Patients With Chronic Bronchitis and COPD: Frequency and Associated Consequences For Systemic Inflammation and Physical Inactivity. Chest. 2009 Jun 19. [Epub ahead of print].
58. Carlsson AC, Wändell PE, Halldin M, et al. Is a unified definition of metabolic syndrome needed? Comparison of three definitions of metabolic syndrome in 60-year-old men and women. Metab Syndr Relat Disord 2009;7(3):231-41.